[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-neuropathic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-neuropathic-pain":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100646184","effectiveness-of-pain-neuroscience-education-along-with-neural-mobilization-versus-neural-mobilization-alone-on-pain-functional-disability-and-quality-of-life-in-patients-with-diabetic-neuropathic-pain-100646184",false,"NCT07695181","Effectiveness of Pain Neuroscience Education Along With Neural Mobilization Versus Neural Mobilization Alone on Pain, Functional Disability And Quality of Life In Patients With Diabetic Neuropathic Pain","Inclusion Criteria:\n\nAge ≥ 40 years (WHO 2016 criteria) Diagnosed Type II diabetes mellitus Lower limb neuropathic pain ≥ 3 months Pain intensity ≥ 4\u002F10 on NPRS Able to walk independently and follow instructions\n\nExclusion Criteria:\n\nNeurological disorders (e.g. stroke, Guillain-Barré) Lumbar disc herniation with radiculopathy Lower limb surgery or spinal fracture within 6 months Active diabetic foot ulcer Diagnosed cognitive impairment or severe infection","ALL","40 Years",{"count":18,"type":19},40,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a randomized controlled trial aims to evaluate the comparative effect of Pain Neuroscience Education combined with neural mobilization versus neural mobilization alone in patients with diabetic neuropathic pain. This study will Compare pain intensity between intervention groups and assess functional disability outcomes. Furthermore, this will evaluate changes in quality of life and to analyze pain-related beliefs following PNE.",[25],"Diabetic Neuropathic Pain","NOT_YET_RECRUITING","2026-07-06",{"date":29,"type":30},"2026-07-10","ACTUAL",{"date":29,"type":19},{"date":33,"type":19},"2027-01-20",{"name":35,"class":36},"Ibadat International University, Islamabad","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100515037","phase-2-a-master-protocol-study-ly900028-of-multiple-intervention-specific-appendices-isas-in-participants-with-chronic-pain-100515037","NCT05986292","A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain","A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain","CPMP","Inclusion Criteria:\n\n* have a visual analog scale (VAS) pain value \\>40 and \\\u003C95 at screening and prerandomization screening.\n* have a history of daily pain for at least 12 weeks based on participant report or medical history\n* have a value of ≤30 on the pain catastrophizing scale\n* have a body mass index \\\u003C40 kilogram\u002Fsquare meter (kg\u002Fm²) (inclusive)\n* are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.\n* are willing to discontinue all medications taken for chronic pain conditions, except rescue medication for the duration of the study\n\nExclusion Criteria:\n\n* have second- or third-degree atrioventricular (AV) heart block or AV dissociation or history of ventricular tachycardia\n* have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques)\n* have surgery planned during the study for any reason, related or not to the disease state under evaluation.\n* have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.\n* have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.\n* have fibromyalgia\n* have substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)\n* have any clinically important abnormality at screening, as determined by investigator, in physical or neurological examination, vital signs, electrocardiogram (ECG), or clinical laboratory test results that could be detrimental to the participant or could compromise the study.\n* have a positive human immunodeficiency virus (HIV) test result at screening\n* have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening.","18 Years",{"count":48,"type":19},10000,[50],"PHASE2","The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-state addenda (DSA) and intervention-specific appendices (ISAs). The ISAs may start independently of other ISAs as interventions become available for clinical testing.",[53,25,54],"Osteoarthritis, Knee","Chronic Low-back Pain","RECRUITING","2026-06-19",{"date":58,"type":30},"2026-06-23",{"date":60,"type":30},"2020-01-30",{"date":62,"type":19},"2027-04",{"name":64,"class":65},"Eli Lilly and Company","INDUSTRY",64]